Form 4: Acrivon Therapeutics Executives Report Stock Transactions

Acrivon Therapeutics, Inc. executives Peter Blume-Jensen and Kristina Masson have reported transactions involving restricted stock units and common stock.

Summary

• Peter Blume-Jensen, President and CEO, and Director, reported the acquisition of 180,095 shares of Common Stock, valued at $0, and the disposition of 2,259,046 shares.
• Kristina Masson, EVP - Business Operations, and Director, also reported transactions related to Common Stock.
• The transactions occurred on May 18, 2026.
• Footnote 1 explains that 180,095 shares represent restricted stock units (RSUs) with vesting schedules tied to continuous service.
• Footnotes 2 and 3 clarify that certain securities are held by one spouse but beneficial ownership is disclaimed by the other, except for pecuniary interest, due to their marital relationship.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports standard insider transactions including both acquisitions of RSUs and dispositions of shares without providing significant new strategic or financial information.

Positives

• Peter Blume-Jensen acquired 180,095 restricted stock units, indicating continued equity incentive.
• The reporting of these transactions demonstrates transparency in executive compensation and ownership.

Negatives

• Peter Blume-Jensen disposed of 2,259,046 shares of Common Stock, which could be interpreted as a significant reduction in direct holdings.
• The reported value of acquired shares is $0, which is typical for RSU grants but may appear unusual without context.

Risks

• The disposition of a large number of shares by a key executive could be perceived negatively by the market, potentially impacting share price.
• Vesting schedules for RSUs are contingent on continuous service, implying a risk of forfeiture if employment terminates before vesting dates.

Future Outlook

The future outlook is not directly addressed in this Form 4 filing, which primarily reports past transactions. However, the vesting schedule for RSUs indicates future potential equity grants contingent on continued employment.

Management Comments

• Dr. Peter Blume-Jensen and Dr. Kristina Masson disclaim beneficial ownership of securities held by each other, except to the extent of their pecuniary interest therein, due to their marital relationship.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider stock transactions in the biotechnology and pharmaceutical sectors, reflecting typical executive compensation structures involving equity awards and potential sales.

Related Party Transactions

• Disclosed spousal relationship between Peter Blume-Jensen and Kristina Masson, with disclaimers of beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the disposition of a significant number of shares by executives as a potential signal, though the context of RSUs and spousal holdings needs consideration.
• Employees whose continuous service is a condition for RSU vesting are directly impacted by the terms of these equity awards.

Next Steps

• Vesting of remaining RSUs in substantially equal quarterly installments after November 18, 2026, subject to continuous service.

Key Dates

Keywords

Form 4, SEC Filing, Acrivon Therapeutics, ACRV, Peter Blume-Jensen, Kristina Masson, Stock Transaction, Beneficial Ownership, Restricted Stock Units, RSU, Executive Compensation